Augmentation therapy with alpha-1 antitrypsin: 20 Year- follow-up of a deficient patient;Traitement substitutif par alpha-1 antitrypsine: Suivi sur 20 ans d'un patient déficitaire

Revue des Maladies Respiratoires

Volumn 25, Issue 9, 2008, Pages 1136-1141

  Pujazon, M C ^a   Carles, P ^a  

^a SERVICE DE PNEUMOLOGIE   (France)

Author keywords

Alfalastin; Emphysema; FEV1 PIZZ; 1 Antitrypsin

Indexed keywords

ALPHA 1 ANTITRYPSIN; BECLOMETASONE; CORTICOSTEROID DERIVATIVE; SALBUTAMOL;

ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE COURSE; DYSPNEA; FOLLOW UP; FRANCE; HUMAN; KINESIOTHERAPY; LUNG EMPHYSEMA; MALE; PHENOTYPE; REHABILITATION CARE; SPIROMETRY; TREATMENT OUTCOME;

EID: 58149118087     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0761-8425(08)74986-6     Document Type: Article

References (16)

1. American Thoracic Society/European Respiratory Society Statement : Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency. Am J Respir Crit Care Med 2003 ; 168 : 818-900.
2. Blanco I : Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries. Eur Respir J 2006 ; 27 : 77-84.
3. Cuvelier A : Le déficit en alpha-1 antitrypsine. Rev Mal Respir 2007 ; 24 : 7-17.
4. Thabut G : Cohorte nationale de patients emphysémateux déficitaires en alpha-1 antitrypsine. Rationnel et mise en place. Rev Mal Respir 2005 ; 22 : 1053-7.
5. The Alpha-1-Antitrypsin Deficiency Registry Study Group : Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. Am J Respir Crit Care Med 1998 ; 158 : 49-59.
6. Alfalastin®. Résumé des caractéristiques du produit - Vidal 2008.
7. Seersholm N, Kok-Jensen A : Survival in relation to lung function and smoking cessation in patients with severe hereditary alpha 1-antitrypsin deficiency. Am J Respir Crit Care Med 1995 ; 151 : 369-73.
8. Knebel AR, Leidy NK, Sherman S : Health related quality of life and disease severity in patients with alpha-1 antitrypsin deficiency. Qual Life Res 1999 ; 8 : 385-91.
9. Needham M, Stockley RA : Exacerbations in {alpha}1-antitrypsin deficiency. Eur Respir J 2005 ; 25 : 992-1000.
10. Abboud RT, Ford GT, Chapman KR : Alpha1-antitrypsin deficiency : a position statement of the Canadian Thoracic Society. Can Respir J 2001 ; 8 : 81-2.
11. Carles P, Constans J, Pujazon MC, Arnaud J, Lauque D, Goudemand M : Evaluation after 2 years of substitutive treatment of PiZZ emphysema with alpha-1 antitrypsin. 9 cases. Presse Med 1990 ; 19 : 514-8.
12. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, Skovgaard LT, Kok-Jensen A, Rudolphus A, Seersholm N, Vrooman HA, Reiber JH, Hansen NC, Heckscher T, Viskum K, Stolk J : A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999 ; 160 : 1468-72.
13. Stoller JK, Fallat R, Schluchter MD, O'Brien RG, Connor JT, Gross N, O'Neil K, Sandhaus R, Crystal RG : Augmentation therapy with alpha1-antitrypsin : patterns of use and adverse events. Chest 2003 ; 123 : 1425-34.
14. Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok-Jensen A, Konietzko N : Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997 ; 10 : 2260-3.
15. Wencker M, Fuhrmann B, Banik N, Konietzko N ; Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen : Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest 2001 ; 119 : 737-44.
16. Lieberman J : Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000 ; 118 : 1480-5.